Abstract
Genetic and biochemical evidence continues to implicate the production and accumulation of the Aβ42 peptide as the causative factor in Alzheimers disease (AD). Thus, a variety of strategies have been developed to decrease the production and/or aggregation of this peptide, which may be clinically useful for the treatment of this devastating disorder. Recently, the discovery that some non-steroidal anti-inflammatory drugs (NSAIDs) appear to selectively decrease the production of Aβ42 has opened a novel therapeutic avenue for AD treatment that may circumvent potential toxicity associated with long-term global inhibition of γ-secretase activity. One drug from this class of compounds, R-flurbiprofen, has advanced to phase 3 clinical trials and may soon provide insight into the viability of this strategy for the prevention or treatment of AD. Delineating the target and mechanism of these compounds is essential for developing new agents with increased potency and optimized pharmacologic properties. The evidence indicating that these chemicals modulate the production of Aβ peptides by directly interacting with the γ-secretase complex is summarized.
Current Topics in Medicinal Chemistry
Title: Possible Mechanisms of Action of NSAIDs and Related Compounds that Modulate γ - Secretase Cleavage
Volume: 8 Issue: 1
Author(s): Thomas Kukar and Todd E. Golde
Affiliation:
Abstract: Genetic and biochemical evidence continues to implicate the production and accumulation of the Aβ42 peptide as the causative factor in Alzheimers disease (AD). Thus, a variety of strategies have been developed to decrease the production and/or aggregation of this peptide, which may be clinically useful for the treatment of this devastating disorder. Recently, the discovery that some non-steroidal anti-inflammatory drugs (NSAIDs) appear to selectively decrease the production of Aβ42 has opened a novel therapeutic avenue for AD treatment that may circumvent potential toxicity associated with long-term global inhibition of γ-secretase activity. One drug from this class of compounds, R-flurbiprofen, has advanced to phase 3 clinical trials and may soon provide insight into the viability of this strategy for the prevention or treatment of AD. Delineating the target and mechanism of these compounds is essential for developing new agents with increased potency and optimized pharmacologic properties. The evidence indicating that these chemicals modulate the production of Aβ peptides by directly interacting with the γ-secretase complex is summarized.
Export Options
About this article
Cite this article as:
Kukar Thomas and Golde E. Todd, Possible Mechanisms of Action of NSAIDs and Related Compounds that Modulate γ - Secretase Cleavage, Current Topics in Medicinal Chemistry 2008; 8 (1) . https://dx.doi.org/10.2174/156802608783334042
DOI https://dx.doi.org/10.2174/156802608783334042 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Genetic Susceptibility to Prion Diseases in Humans and Mice
Current Genomics “Connecting the Dots” from Blood Brain Barrier Dysfunction to Neuroinflammation and Alzheimer’s Disease
Current Neurovascular Research Free Radical Attack on Cholesterol: Oxysterols as Markers of Oxidative Stress and as Bioactive Molecules
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) The Implications of Autophagy in Alzheimer’s Disease
Current Alzheimer Research Copper and Heme-Mediated Abeta Toxicity: Redox Chemistry, Abeta Oxidations and Anti-ROS Compounds
Current Topics in Medicinal Chemistry (±)-3,5-Bis(substitutedmethyl)pyrrolidines: Application to the Synthesis of Analogues of glycine-L-proline-L-glutamic Acid (GPE)
Current Organic Synthesis Multi-Target Directed Drugs: A Modern Approach for Design of New Drugs for the treatment of Alzheimer’s Disease
Current Neuropharmacology Chondroitin Sulfate, a Major Niche Substance of Neural Stem Cells, and Cell Transplantation Therapy of Neurodegeneration Combined with Niche Modification
Current Stem Cell Research & Therapy Clinical and Rehabilitative Management of Retinitis Pigmentosa:Up-to-Date
Current Genomics Applications of High Content Screening in Life Science Research
Combinatorial Chemistry & High Throughput Screening Drug Treatment of Obesity: Established and Emerging Therapies
Mini-Reviews in Medicinal Chemistry NAP and ADNF-9 Protect Normal and Downs Syndrome Cortical Neurons from Oxidative Damage and Apoptosis
Current Pharmaceutical Design Disentangling the Role of the Tau Gene Locus in Sporadic Tauopathies
Current Alzheimer Research Apathy: A Conceptual Review
Current Psychiatry Research and Reviews Specific Targeted Therapy: A New Tool for the Destruction of Cancer
Current Drug Therapy Ethnobotanical Treatment Strategies Against Alzheimers Disease
Current Alzheimer Research Identification of Potent Caspase-3 Inhibitors for Treatment of Multi- Neurodegenerative Diseases Using Pharmacophore Modeling and Docking Approaches
CNS & Neurological Disorders - Drug Targets Highly Organized Nanostructures for Brain Drug Delivery - New Hope or Just a Fad?
CNS & Neurological Disorders - Drug Targets Synthesis and Cholinesterase Inhibitory Activity of N-Phosphorylated/ N-Tiophosphorylated Tacrine
Medicinal Chemistry Integration of <sup>18</sup>FDG-PET Metabolic and Functional Connectomes in the Early Diagnosis and Prognosis of the Alzheimer's Disease
Current Alzheimer Research